HomeInvestors & MediaNews
- Celgene’s BCMAxCD3 Clinical Trial Data Attracts Attention from American Society of Hematology
Bio’s BCMAx4-1BB Bispecific Antibody Expected to Show Better Efficacy and
Stability Compared to Previous BCMAxCD3
December 10, 2019 - After BCMAxCD3 by Celgene Corporation (“Celgene”) garnered attention from the American Society of Hematology, ABL Bio, Inc. (“ABL Bio”) has been the topic of conversation with its announcement of BCMAx4-1BB Bisepcific Antibody (BsAb) that combines CD3 with another immune modulation target 4-1BB.
It is known that Celgene’s BCMAxCD3 BsAb CC-93269, which had entered
its clinical trial this April, achieved 88.9% of overall response rate (ORR)
including high stringent complete response/complete response (sCR/CR) rate of
44.4% after administering high dose (10 mg) to patients of late-stage multiple
myeloma, a cancer that has no suitable drugs.
Compared to Celgene’s BCMAxCD3 BsAb, ABL Bio’s BCMAx4-1BB BsAb has no
cytokine release syndrome (CRS), which is prevalent in CD3. In addition, while
CD3 activates only the T-cells among human immune cells, 4-1BB engages with not
only T-cells but also natural killer (NK) cells, making it a platform that is
expected to perform remarkably better in terms of efficacy. In the case of ABL
Bio’s 4-1BB platform, it has been proven to be superior in terms of stability,
as it has resolved the issue of liver toxicity. The superiority of ABL Bio’s
BCMAx4-1BB BsAb is gaining attention also because its half-life is
overwhelmingly longer than that of BiTE platform-based BCMAxCD3 by Amgen.
For BCMA CAR-T, which was the hot topic in last year’s American Society
of Hematology, there is the challenge of creating patient-specific
therapeutics. In case of BsAb, however, it is in the spotlight because not only
is it easy to administer but also has better market opportunity than CAR-T in
terms of price. Expressing strong confidence in the company’s BCMAx4-1BB BsAb,
Sang Hoon Lee, the founder and CEO of ABL Bio, said, “Our BCMAx4-1BB is
currently in preclinical stage but once it enters the clinical trial, it is
expected to show better efficacy than Celgene’s CC-93269, as well as superb
data in terms of stability.” This BsAb is currently under joint research and
development with ABL Bio’s partner company TRIGR in the US and
Dt&SanoMedics in Korea.
In January of next year at the JP Morgan conference, ABL Bio and global big pharmas will have serious discussions not only on ABL Bio’s multiple BsAb-based immuno-oncology but also ABL301, a BsAb for treating Parkinson’s Disease, which is combined with blood brain barrier (BBB) penetration platform. This event will be of great interest to the industry as ABL Bio is expected to release data on ABL301 in comparison with that of Roche’s BsAb-base